Open Air Scholar

Design:

The study validated the SpecID system through controlled experiments using saliva samples spiked with viral particles and clinical samples. Researchers tested the system’s sensitivity, specificity, and ability to distinguish genetically similar viruses and SARS-CoV-2 variants. The platform was compared to PCR in terms of detection limits and turnaround time. Experiments included analysis of coronaviruses (canine, human OC43, bovine Mebus), SARS-CoV-2 variants (Delta, Omicron), and cucumber leaf spot virus (CLSV).

Procedures:

The SpecID workflow involves depositing saliva onto a stainless-steel mesh holder, followed by ionization via argon plasma sparks (~2.3 keV) generated by a modified Compact Mass Spectrometer (CMS). The system’s RSD software processes spectral data through binning, noise reduction, and normalization, enabling real-time analysis. Key technical components include a redesigned ionization chamber with optimized discharge needle positioning and replicate-based spectral analysis. Validation involved testing heat-inactivated SARS-CoV-2 strains (collaborating with the FDA) and diverse human saliva samples to account for compositional variability.

Primary Findings:

The SpecID system detected as few as 500 viral particles/0.5 mL saliva, matching PCR’s sensitivity but with results in under a minute. It successfully differentiated genetically similar coronaviruses (e.g., bovine vs. human OC43) and SARS-CoV-2 variants (Delta vs. Omicron) using unique spectral signatures. The limit of detection (LOD) for CLSV in spiked saliva was 10³ virions/mL. Principal component analysis (PCA) clustered virus-positive and -negative samples distinctly, confirming the system’s specificity. Human saliva samples from diverse donors yielded consistent results, while artificial saliva proved unreliable due to compositional differences.

Secondary Findings:

The system’s portability and lack of reagent dependency enable field use without sample preparation. SEM images of the mesh holder and TEM micrographs of viral particles validated the ionization process. The RSD software automated spectral analysis, reducing interpretation time. The platform’s versatility was demonstrated through potential applications in detecting influenza, hepatitis, and HIV, alongside environmental monitoring and industrial quality control.

Interpretation:

The SpecID system overcomes PCR’s limitations by eliminating amplification steps and reagent dependency, reducing false negatives and enabling rapid, on-site diagnostics. Its ability to distinguish viral variants in real time supports outbreak surveillance and personalized medicine. The reliance on saliva—a non-invasive, stable sample—enhances accessibility in resource-limited settings. Spectral databases will be critical for automating pathogen identification and detecting novel variants.

Strengths:

Key strengths include speed (results <1 minute), minimal preprocessing, and adaptability across pathogens and matrices. The system’s portability and scalability make it suitable for point-of-care testing and large-scale surveillance. The use of human saliva samples from diverse donors underscores its robustness against compositional variability.

Limitations:

Saliva composition variability (e.g., diet, medications) may affect results, though human samples showed consistency. The need for a comprehensive spectral database limits current identification to known pathogens. While the system excels in variant differentiation, further validation is required for clinical accuracy across diverse populations and pathogens.

Design:

The study employed an in vitro approach to develop the CP2-resistant LaR strain through stepwise exposure to increasing drug concentrations. Wild-type (La) and LaR strains were compared using biochemical, genetic, and pharmacological assays. Key experiments included viability testing, mitochondrial function analysis, and cross-resistance profiling against established antileishmanial drugs (pentamidine, miltefosine) and topoisomerase inhibitors (camptothecin, topotecan).

Procedures:

Viability was assessed via MTT-based assays to determine IC₅₀ values. Mitochondrial function was evaluated using oxygen consumption rate (OCR) measurements, enzyme activity assays for ubiquinol-cytochrome c reductase (CcR, complex III), and flow cytometry to quantify reactive oxygen species (ROS) and mitochondrial membrane potential (Δψm). Real-time PCR (RT-qPCR) analyzed gene expression of electron transport chain (ETC) components. Cross-resistance was tested using camptothecin (Top1B inhibitor), pentamidine (DNA minor groove binder), and miltefosine (lysophospholipid). Calcium dysregulation pathways were explored using calcium channel blockers (verapamil, cyclosporine A) and the mitochondrial calcium uniporter (MCU) inhibitor ruthenium red (RuRed).

Primary Findings:

The LaR strain exhibited a four-fold higher IC₅₀ (52.4 μM) compared to wild-type La (13.2 μM). Cross-resistance analysis revealed LaR was resistant to camptothecin (a Top1B inhibitor) but more susceptible to pentamidine and miltefosine. LaR maintained similar infectivity in murine macrophages as La, indicating resistance did not impair virulence. Mechanistically, CP2 inhibited complex III (CcR), reducing OCR by 55% in La versus 30% in LaR. LaR showed reduced sensitivity to antimycin A (complex III inhibitor), correlating with overexpression of CcR (confirmed by RT-qPCR). CP2 induced ROS accumulation in La but not LaR, aligning with its lower Δψm disruption. LaR also exhibited impaired mitochondrial calcium uptake via the MCU, as evidenced by increased sensitivity to RuRed.

Secondary Findings:

ETC inhibitor profiling showed La was more sensitive to complex I (rotenone) and IV (KCN) inhibitors than LaR, suggesting metabolic adaptations in LaR. Calcium channel blockers (verapamil, cyclosporine A) and DTT partially rescued La from CP2 toxicity but had no effect on LaR. OCR measurements under glucose conditions indicated LaR relied more on oxidative phosphorylation, while pyruvate-driven respiration highlighted complex I's role. Despite La's higher ATP production (state 3 respiration), both strains reached similar maximal respiration rates, with LaR's basal OCR being 30% higher. No significant changes in other ETC complex genes were observed except for CcR overexpression in LaR, even without CP2 exposure.

Interpretation:

LaR's resistance arises primarily from CcR overexpression, which compensates for CP2-induced inhibition of complex III, reducing ROS production and maintaining mitochondrial function. Cross-resistance to camptothecin suggests CP2's dual action on Top1B and mitochondria, while increased susceptibility to pentamidine/miltefosine implies distinct resistance mechanisms for these drugs (e.g., altered drug transport). The study highlights mitochondrial adaptations as central to resistance, with LaR's enhanced glucose oxidation and defective MCU contributing to survival under CP2 stress. These findings contrast with prior resistance models linked to Δψm loss or efflux pumps, underscoring the complexity of Leishmania's adaptive strategies.

Strengths:

The study employed a rigorous in vitro resistance selection model, combined biochemical and genetic approaches, and integrated cross-resistance data to dissect pleiotropic effects. The use of OCR and mitochondrial isolation provided mechanistic insights into ETC targeting.

Limitations:

The in vitro model may not fully replicate in vivo resistance dynamics. The exact genetic mutations driving CcR overexpression remain uncharacterized, and long-term resistance stability was not assessed. Additionally, the role of Top1B in resistance requires further clarification, as LaR showed resistance only to camptothecin, not topotecan.

Design:

A randomized controlled trial was conducted in two Istanbul hospitals from June to December 2021, enrolling 94 mechanically ventilated adults (excluding those under 18, with pre-existing VAP, SARS-CoV-2 infection, or anatomical barriers to prone positioning). Participants were divided into prone (n=40) and non-prone control (n=40) groups using block randomization. The prone group underwent daily 4–6-hour face-down positioning for at least five days, while controls received standard supine care. Ethical approval was obtained, and adaptive recruitment strategies addressed high attrition (8 prone and 4 non-prone participants excluded due to transfers, mortality, or withdrawal).

Procedures:

Key outcomes included ventilator settings (FiO₂, tidal volume, PEEP), arterial blood gas parameters (pH, PaO₂, PaCO₂, SaO₂), and VAP assessed via Clinical Pulmonary Infection Score (CPIS). Measurements were taken pre-intervention, during prone positioning, and post-return to supine. Statistical analyses used t-tests, Mann-Whitney U tests, and repeated-measures ANOVA to compare groups. Nursing protocols standardized prone positioning techniques, and ventilator modes were maintained consistently across both groups.

Primary Findings:

The prone group demonstrated statistically significant improvements in oxygenation: higher PaO₂/FiO₂ ratios (p=0.001), reduced FiO₂ requirements (60% vs. 45% on Day 5, p<0.001), increased tidal volumes (500 ± 50 mL vs. 420 ± 45 mL on Day 2, p<0.05), and better oxygen saturation (97% ± 2% vs. 94% ± 3%, p=0.004). Arterial blood gas analysis showed improved pH (7.41 vs. 7.38, p=0.023) and lower PaCO₂ in the prone group. However, VAP incidence, measured by CPIS, did not differ significantly between groups (4.5 ± 1.0 vs. 4.2 ± 0.9, p=0.081).

Secondary Findings:

Hemodynamic changes included higher systolic (132.5 ± 5.6 vs. 128.3 ± 4.9 mmHg, p=0.025) and diastolic blood pressure (84.6 ± 3.2 vs. 80.9 ± 2.8 mmHg, p=0.040) in the prone group on Day 5, alongside increased heart rate (cumulative change: +15.3 ± 2.1 bpm vs. +9.8 ± 1.9 bpm, p=0.001). PEEP levels remained stable across both groups. While prone positioning did not reduce VAP rates, CPIS scores trended higher in the experimental group, suggesting potential risks of prolonged intubation.

Interpretation:

Prone positioning significantly enhanced oxygenation and ventilator efficiency, supporting its use in hypoxemic patients. However, the lack of VAP reduction contrasts with prior ARDS-focused studies, possibly due to shorter prone durations or patient selection criteria. Hemodynamic changes highlight the need for close monitoring, particularly in patients with cardiovascular instability. The trend toward higher CPIS scores in the prone group warrants further investigation into infection risks associated with prolonged positioning.

Strengths:

Standardized protocols ensured consistent intervention delivery, and repeated-measures analysis captured longitudinal changes. Ethical approval and adaptive recruitment maintained statistical power despite high attrition in critically ill populations.

Limitations:

Unblinded providers may have introduced bias, and selection criteria excluded certain high-risk groups (e.g., obese patients). The study’s retrospective registration and reliance on CPIS—a subjective VAP measure—limit generalizability.

Design:

The study employed in vitro and in vivo models to evaluate LHN efficacy. In vitro experiments used neutrophils from severe ARDS patients and murine models of LPS-induced ALI. In vivo studies included survival analysis, lung histology, and functional assessments in mice. Biodistribution and safety were evaluated using Cy5.5-labeled LHN and biochemical markers.

Procedures:

LHN were synthesized via thin-film dispersion, incorporating cationic lipid (DDAB) and 25-HC, with DNase-1 surface-coated to preserve enzymatic activity. Characterization included size (mean diameter: 109.3 nm unloaded, 201.9 nm DNase-1-conjugated), zeta potential (+24.6 to +24.8 mV), and encapsulation efficiency (78.9% for sivelestat). In vitro testing measured extracellular DNA (SYTOX Green), cytokines (IL-1β, IL-6, IL-8, IL-17A), and enzyme activity (myeloperoxidase, neutrophil elastase). In vivo studies assessed lung compliance (flexiVent), fibrosis (collagen I, hydroxyproline), and survival rates. Biodistribution tracked lung retention via 25-HC/DDAB targeting, while safety data included organ function markers and hematologic parameters.

Primary Findings:

LHN reduced extracellular DNA by 60% in patient neutrophils and plasma cell-free DNA (cfDNA) by 40%, outperforming free sivelestat or DNase-1 alone. In murine models, LHN improved 10-day survival to 40% (vs. 0% in LPS + PBS controls and 10% in free drug-treated mice). Lung histology showed reduced neutrophil infiltration, edema, and hyaline membranes, with improved compliance and lung volumes. Biodistribution confirmed lung-targeted accumulation (up to 24 hours) and minimal off-target organ uptake. In vivo NET staining (SYTOX Orange) revealed a 50% reduction in NETs, corroborating in vitro results.

Secondary Findings:

LHN suppressed fibrosis markers (collagen I deposition, hydroxyproline levels) and pro-inflammatory cytokines (IL-1β, IL-6, IL-8, HMGB1). Cytokine arrays in patient plasma showed reduced IL-17A and chemokines (CXCL10, CXCL11, CXCL15). Safety data indicated no hepatorenal toxicity or hematologic adverse effects. DNase-1 retained robust DNA-degrading activity in vitro, and sivelestat improved neutrophil viability. Collagen deposition and epithelial apoptosis were also attenuated.

Interpretation:

The LHN’s dual mechanism—blocking NETosis via sivelestat and degrading existing NETs via DNase-1—synergized with 25-HC’s anti-inflammatory effects (via NF-κB/SREBP2 pathways) to disrupt the inflammatory-fibrotic cycle. Targeted lung delivery via DDAB and 25-HC minimized systemic toxicity, enhancing efficacy. Reduced cfDNA and cytokines suggest LHN mitigates immune dysregulation, while fibrosis suppression addresses long-term lung damage. The findings align with clinical relevance in severe COVID-19, where elevated cfDNA and NETs correlate with poor outcomes.

Strengths:

The study combines targeted drug delivery with dual anti-inflammatory and anti-NET mechanisms, addressing key pathogenic pathways. In vitro and in vivo validation, along with safety data, strengthens translational potential. The use of patient-derived neutrophils and fibroproliferative mouse models enhances clinical relevance.

Limitations:

The murine model may not fully replicate human ARDS complexity, particularly in chronic fibrosis. Long-term safety and optimal dosing in humans remain untested. Additionally, while 25-HC enhances targeting, its mechanism in lung homing requires further exploration.

Design:

The study is a comprehensive review of existing literature on AATD, integrating data from clinical trials, observational studies, and biomarker research. It evaluates the efficacy of AAT augmentation therapy, emerging therapies (e.g., RNA interference, gene editing), and diagnostic strategies. The review also analyzes barriers to treatment access and the role of biomarkers like desmosine, C-reactive protein (CRP), and imaging modalities such as CT densitometry.

Procedures:

Key methodologies include analysis of clinical trial outcomes (e.g., RAPID-RCT, SPARTA), biomarker validation studies (e.g., fibrinopeptides, elastin-derived peptides), and observational data on disease progression. The review assesses diagnostic protocols (e.g., PredictAAT tool integrating CRP levels), lung function metrics (FEV1, lung clearance index), and imaging techniques. Emerging therapies, such as recombinant AAT and antisense oligonucleotides, are evaluated for their potential to address liver and lung dysfunction.

Primary Findings:

AAT augmentation therapy slows lung density loss as measured by CT densitometry, even when FEV1 declines plateau. Survival benefits are mixed: one study noted reduced mortality in treated patients, but a 7-year trial failed to confirm this. However, treated patients showed slower quality of life (QoL) decline. Biomarkers like urinary desmosine (reflecting elastin breakdown) and CRP (indicating inflammation) correlate with disease progression and therapy efficacy. Underdiagnosis remains a critical issue, with only ~0.35% of cases globally identified. Smoking exacerbates lung damage in PiZZ individuals, even among nonsmokers.

Secondary Findings:

Genotype variability influences outcomes: PiZZ patients face the highest lung disease risk, while PiMZ/SZ carriers may develop symptoms only with environmental triggers. Lung clearance index (LCI) shows promise for early detection in younger patients but requires standardization. Emerging therapies, such as RNA interference (e.g., fazirsiran) and CRISPR-based gene editing, target liver and lung dysfunction. Challenges include inconsistent AAT therapy access, variable reimbursement policies, and limited sample sizes in rare disease trials.

Interpretation:

The protease-antiprotease imbalance, driven by insufficient AAT to inhibit neutrophil elastase, remains central to lung degradation. However, emerging evidence highlights the role of neutrophilic inflammation and other proteases (e.g., proteinase 3) in disease progression. Biomarkers and CT densitometry provide sensitive measures of disease activity, though FEV1 remains a common but imperfect endpoint. The survival benefit of AAT therapy is inconclusive, underscoring the need for long-term studies. Early diagnosis via COPD screening and incidental CT scans could improve case identification, while standardized protocols are critical for global care.

Strengths:

The review synthesizes diverse data, emphasizing biomarkers and imaging as key tools for diagnosis and monitoring. It highlights the multifaceted nature of AATD management, including smoking cessation and pulmonary rehabilitation. The inclusion of emerging therapies offers hope for future treatment options.

Limitations:

The reliance on observational studies and small clinical trials limits definitive conclusions on survival benefits. Heterogeneity in diagnostic approaches and treatment access across regions complicates global comparisons. CT densitometry’s radiation exposure and variability in imaging protocols pose practical challenges.

Design:

A large-scale cohort study analyzing real-world data from 268,844 individuals tested for spike protein antibodies using the Elecsys® Anti-SARS-CoV-2 S assay. Participants were followed for 12 months post-testing to track symptomatic infections (via ICD-10 codes) and severe outcomes (hospitalization, ICU admission, intubation, or death). The study employed inverse probability weighting and Cox proportional hazards models to adjust for confounders like age, comorbidities, and vaccination history.

Procedures:

Antibody levels were quantified using the Elecsys assay, which measures binding antibodies to the spike protein’s receptor-binding domain. Outcomes were identified through medical claims data. Subgroup analyses evaluated protection across age groups, immunocompromised status, and variant-specific effects (Delta vs. Omicron). Statistical methods included boosted regression trees for propensity score estimation and Cox regression to assess hazard ratios (HRs) for infection and severity risks.

Primary Findings:

A dose-dependent inverse relationship between antibody levels and reinfection risk was observed. Individuals with ≥0.8–<1,000 U/mL had a 42% lower risk of symptomatic infection (HR 0.58, 95% CI 0.55–0.61) compared to those <0.8 U/mL. Those with ≥2,500 U/mL saw a 62% reduction (HR 0.38, 95% CI 0.36–0.39). For severe outcomes, ≥2,500 U/mL reduced risk by 87% (HR 0.13, 95% CI 0.11–0.15). Variant analysis showed stronger protection against Delta (≥2,500 U/mL: HR 0.10) than Omicron (HR 0.28).

Secondary Findings:

Protection was consistent across age groups but less pronounced in immunocompromised individuals. Subgroup analyses confirmed the trend of higher antibody levels correlating with lower risk, though baseline demographics and comorbidities influenced outcomes. The study also noted underreporting of asymptomatic cases due to reliance on claims data and potential biases in variant classification based on time periods rather than genomic sequencing.

Interpretation:

Higher spike protein antibody levels strongly correlate with reduced reinfection and severe disease risk, emphasizing their role as a biomarker for immunity. The findings suggest antibody thresholds (e.g., ≥2,500 U/mL) could guide personalized vaccination strategies, particularly for high-risk groups. However, variant-specific efficacy highlights the need for ongoing monitoring as SARS-CoV-2 evolves.

Strengths:

The study’s large sample size and real-world design provide robust evidence for antibody-mediated protection. Integration of lab and claims data enabled comprehensive outcome tracking, while statistical adjustments minimized confounding effects. The Elecsys assay’s validated performance ensures reliable antibody quantification.

Limitations:

Generalizability is limited due to reliance on insured populations, excluding uninsured or Medicaid/Medicare beneficiaries. Asymptomatic cases may be underreported, and variant classification lacked genomic confirmation. Additionally, unmeasured factors like antiviral use or behavioral differences could influence results.

Design:

A retrospective cohort study design was employed, analyzing data from 455 elderly CAP patients admitted to a hospital between 2020 and 2024. Participants were followed for 90 days post-admission to assess mortality and survival outcomes. The study used a holistic approach, integrating clinical, psychosocial, and nutritional assessments.

Procedures:

Key measures included the WHO-5 Well-Being Index (mental health), Mini Nutritional Assessment Short Form (MNA-SF, nutritional status), and Charlson Comorbidity Index (CCI, comorbidity burden). Serum albumin, C-reactive protein (CRP), and clinical variables (e.g., white blood cell count, blood urea nitrogen) were also analyzed. Statistical methods included Spearman’s correlation, logistic regression, Kaplan–Meier survival analysis, and Bootstrap-based mediation analysis. Multiple imputation addressed missing data, and robust statistical techniques ensured validity.

Primary Findings:

The 28-day mortality rate was 9.67%, rising to 12.31% at 90 days. Spearman’s correlation revealed strong positive associations between WHO-5 scores and MNA-SF scores (r = 0.560) and albumin levels (r = 0.245), while negative correlations were observed with CCI (r = -0.202) and CRP (r = -0.242). Kaplan–Meier analysis showed significant survival differences by nutritional status: malnourished patients (MNA-SF ≤7) had 28-day survival rates of 72.4% versus 98.3% for well-nourished patients (MNA-SF 12–14; χ² = 83.214, P < 0.001). Logistic regression identified comorbidity (CCI), malnutrition, lower well-being (WHO-5), CAP severity, and mechanical ventilation as significant predictors of mortality. Mediation analysis indicated that mental well-being and nutritional status mediated 34.8% (28-day) and 34.2% (90-day) of the total effect of comorbidity burden on mortality.

Secondary Findings:

Regression models highlighted the protective effects of higher MNA-SF (β = -0.287, P < 0.001) and WHO-5 scores (β = -0.346, P = 0.004) against mortality. Odds ratios (ORs) showed malnutrition (OR = 0.758) and poor mental well-being (OR = 0.764) increased mortality risk. Mediation pathways included direct effects of CCI on mortality and indirect effects via WHO-5 and MNA-SF (e.g., CCI → WHO-5 → mortality contributed 0.230 to the total indirect effect for 28-day mortality). Kaplan–Meier curves (Fig. 2C, D) visually demonstrated stark survival disparities between nutritional groups.

Interpretation:

The study underscores the bidirectional relationship between comorbidity burden, mental health, and nutrition in CAP outcomes. Chronic conditions (CCI) likely exacerbate inflammation and immune dysfunction, while malnutrition impairs recovery. Mental well-being acts as a protective buffer, possibly through stress regulation and treatment adherence. The mediation analysis suggests that addressing mental health and nutrition could mitigate the indirect effects of comorbidities on mortality.

Strengths:

The study’s strengths include its large sample size, use of validated tools (WHO-5, MNA-SF, CCI), and advanced statistical techniques (e.g., mediation analysis). Multiple imputation minimized bias from missing data, and Kaplan–Meier analysis provided clear survival probability comparisons.

Limitations:

Limitations include the retrospective design, which may introduce selection bias. Missing data on CAP severity scores (e.g., CURB-65) and incomplete treatment details limit generalizability. Additionally, mechanical ventilation was used as a proxy for severe CAP, potentially oversimplifying clinical complexity.

Design:

A controlled greenhouse experiment was conducted using tomato plants (Ranniy-83) inoculated with M. hapla. Treatments included four microbial strains, three chemical nematicides, and an untreated control. The study employed a randomized block design with repeated measurements to assess nematode suppression, fruit quality, and yield over time.

Procedures:

Microbial strains and chemical treatments were applied via soil drenching. Biological efficacy was measured by reductions in root galls, while fruit quality parameters included sugar content (°Brix), total acidity (g citric acid/100g), and vitamin C (mg ascorbic acid/100g). Yield was tracked through fruit weight and total production. Statistical analyses (ANOVA, correlation tests) were used to compare treatment effects and identify metabolic correlations under stress.

Primary Findings:

Paecilomyces lilacinus F-22BK/6 and Arthrobotrys conoides F-22BK/4 showed the highest efficacy, reducing galls by 91.8% and 88.4%, respectively, comparable to Vydate 5G (96.8%). These strains improved fruit weight by 8.6–9.9% and yield by 5.0–13.3%. Trichoderma viride F-294 reduced galls by 65.8% but caused a 12% drop in vitamin C levels. Vydate 5G suppressed nematodes effectively but did not enhance yield, while Fitoverm (58.8% efficacy) reduced vitamin C by 15%. Positive correlations between sugar and acidity (e.g., r = 0.6 for Paecilomyces) suggested metabolic resource allocation, whereas inverse correlations (e.g., r = -0.59 for Paecilomyces) indicated antioxidant prioritization over acid synthesis under stress.

Secondary Findings:

Control plants exhibited higher vitamin C levels (28.5 mg/100g) compared to treated groups, except for Paecilomyces (26.1 mg/100g). Trichoderma and Fitoverm treatments disrupted ascorbic acid synthesis, likely due to oxidative stress. Correlation analyses revealed shared metabolic pathways between acidity and vitamin C in untreated plants (r = 0.72), contrasting with stress-induced shifts in microbial-treated plants.

Interpretation:

Microbial strains like Paecilomyces and Arthrobotrys offer effective, eco-friendly alternatives to chemical nematicides, balancing nematode suppression with yield improvements. Their ability to enhance sugar content and maintain fruit quality underscores their potential for sustainable agriculture. However, Trichoderma and Fitoverm’s negative impact on vitamin C highlights the need to prioritize strains that minimize metabolic disruption. The inverse sugar–vitamin C correlations suggest plants prioritize energy mobilization over antioxidant synthesis under stress, aligning with prior studies on plant defense mechanisms.

Strengths:

The study’s controlled greenhouse design minimized environmental variability, while comprehensive biochemical and yield metrics provided holistic insights. Direct comparisons between microbial and chemical treatments strengthened conclusions on efficacy and safety.

Limitations:

Results may not fully reflect field conditions, where environmental factors and pest interactions could influence outcomes. Limited strain combinations and application rates warrant further exploration.

Design:

A cross-sectional study was conducted between August and September 2023, collecting 314 adult Culex tritaeniorhynchus mosquitoes from six sites in Mianyang: Anzhou, Beichuan, Jiangyou, Pingwu, Santai, and Youxian. Mosquitoes were captured using light traps, and species identity was confirmed via mitochondrial COI gene sequencing. DNA was extracted for genetic analysis of target genes linked to insecticide resistance.

Procedures:

PCR amplification targeted regions of VGSC (165 bp), Rdl (182 bp), and AChE (633 bp). Sanger sequencing identified polymorphisms, and haplotypes were inferred from homozygotes. Population genetic analyses tested Hardy-Weinberg equilibrium (HWE) and inter-population differences. Genotype frequencies were compared using exact G-tests. Statistical analyses focused on allele frequencies, mutation prevalence, and geographic variation.

Primary Findings:

1. VGSC L1014F Mutation: The classical kdr mutation (Leu1014Phe) was detected in all six populations, with allele frequencies ranging from 16.98% (Pingwu) to 27.78% (Santai). Resistant homozygotes (TTT genotype) were present in five populations, reaching up to 6.25% in Youxian. 2. Rdl A296S and V327I Mutations: The A296S mutation (Ala296Ser) was identified for the first time in Cx. tritaeniorhynchus, with allele frequencies between 62.04% (Santai) and 94.00% (Anzhou). The V327I mutation (Val327Ile) occurred at low frequencies (0.93–1.8%), primarily in individuals carrying A296S. 3. AChE F455W Mutation: The F455W substitution (Phe455Trp) was nearly fixed in all populations, with allele frequencies exceeding 97% and complete fixation in Anzhou and Youxian.

Secondary Findings:

Exact G-tests revealed significant variation in Rdl-296S mutation distribution across populations but no significant differences for VGSC-1014 or Ace-455 mutations. Santai exhibited lower Rdl-296S allele frequencies compared to other sites, potentially due to differing insecticide use or genetic drift. No population deviated significantly from Hardy-Weinberg equilibrium for any gene.

Interpretation:

The widespread VGSC L1014F mutation indicates ongoing selection pressure from pyrethroid and DDT use, while the near-fixation of AChE F455W highlights strong selection for organophosphate/carbamate resistance. The novel Rdl A296S mutation, linked to dieldrin resistance, suggests a high prevalence of GABA receptor insensitivity. The co-occurrence of multiple mutations complicates vector control, as it implies cross-resistance to multiple insecticide classes. The low prevalence of V327I warrants further study to assess its functional role and interaction with A296S.

Strengths:

The study provides the first molecular evidence of Rdl mutations in Cx. tritaeniorhynchus, enhances understanding of resistance dynamics in JE vectors, and employs rigorous genetic and statistical analyses. The large sample size (314 mosquitoes) and multi-gene approach strengthen the findings.

Limitations:

Phenotypic resistance assays were not conducted, limiting confirmation of reduced insecticide susceptibility. The study excluded metabolic resistance mechanisms (e.g., detoxification enzymes), which may contribute to resistance. Geographic sampling was limited to Mianyang, potentially underrepresenting regional variation.

Design:

The study is a comprehensive review of existing literature analyzing metabolic changes in SARS-CoV-2 infection. It synthesizes data from clinical trials, experimental models, and observational studies to evaluate the impact of viral infection on metabolic pathways and their clinical implications.

Procedures:

Key interventions and analyses included: 1) assessment of metabolic disruptions in infected cells and patients, 2) evaluation of biomarkers (e.g., lactate dehydrogenase, CRP/HDL ratio, arginine/kynurenine ratio) for disease severity prediction, 3) examination of therapeutic strategies (e.g., metformin, statins, amino acid supplementation), and 4) analysis of omics data (proteomic, metabolomic) to identify systemic metabolic shifts. Experimental models, such as hamster studies and in vitro cell cultures, were used to validate findings.

Primary Findings:

SARS-CoV-2 infection disrupts carbohydrate metabolism by impairing pancreatic β-cell function via ACE2 receptor binding, leading to insulin resistance and hyperglycemia. Elevated blood glucose correlates with severe outcomes, prolonged hospitalization, and higher mortality. Lipid metabolism is altered through reduced HDL and LDL levels, lipid droplet hijacking for viral replication, and upregulated fatty acid synthase (FASN). Amino acid metabolism shows deficiencies in arginine, tryptophan, and valine, with tryptophan depletion via the kynurenine pathway linked to immune exhaustion. Key biomarkers include the arginine/kynurenine ratio (≤15.7 distinguishes patients from controls with 100% accuracy) and CRP/HDL ratio, which predict severity and mortality. Therapeutic strategies like FASN inhibitors (e.g., orlistat), arginine supplementation, and α-ketoglutarate reduce viral load and inflammation.

Secondary Findings:

The virus exploits lipid rafts and membrane remodeling for replication, while urea cycle disruption impairs T-cell function. Host genetics and dietary factors (e.g., omega-3 intake) influence metabolic resilience. Long-COVID complications, such as HDL dysfunction and persistent inflammation, are linked to metabolic dysregulation. Combined metabolic activators (CMAs) like L-serine and N-acetyl-L-cysteine accelerate recovery by improving metabolic and inflammatory profiles.

Interpretation:

Metabolic disruptions drive SARS-CoV-2 pathogenesis by impairing immune responses and providing resources for viral replication. Hyperglycemia exacerbates organ damage, while lipid dysregulation promotes thrombosis and inflammation. Amino acid imbalances, particularly arginine and tryptophan deficiencies, weaken immune defenses. Biomarkers like the arginine/kynurenine ratio and CRP/HDL ratio offer non-invasive tools for early risk stratification. Therapeutic strategies targeting multiple metabolic axes (e.g., FASN inhibition, arginine supplementation) may reduce disease severity.

Strengths:

The study provides a holistic view of metabolic pathways in SARS-CoV-2 infection, identifies actionable biomarkers, and highlights translational therapeutic approaches. It integrates clinical, experimental, and omics data to strengthen conclusions.

Limitations:

Validation of biomarkers and therapies in large-scale clinical trials is needed. The complexity of metabolic interactions and host variability may limit generalizability. Long-term effects of interventions remain understudied.